▲ +107.82% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $58.83, with a high forecast of $79.00 and a low forecast of $41.00. The average price target represents a 107.82% upside from the last price of $28.31.
The current consensus among 6 investment analysts is to buy stock in Akero Therapeutics.
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.